PCI vs. CABG in patients aged under 50 years

Original title: Comparison of 30-Day and 5-Year Outcomes of Percutaneous Coronary Intervention Versus Coronary Bypass Grafting in Patients Aged ≤50 Years.  Reference: Fausto Biancari, et al. Am J Cardiology Article in Press.

 

Coronary artery bypass grafting (CABG) is associated with better evolution than percutaneous coronary intervention (PCI), mainly due to left main and multiple vessels re interventions. In ≤50 year old patients, results have not been thoroughly analyzed.

This retrospective analysis included 1617 patients receiving PCI and 592 receiving CABG for multiple vessels disease or left main lesions. Diabetes, renal failure, peripheral vascular disease, severe left main lesion, previous intervention and severe ventricular dysfunction occurred more often in the CABG group.

After propensity score matching, given the different baseline characteristics, 235 patients remained for final analysis. Immediate evolution, late mortality and freedom from cerebrovascular events at 5 years were similar in both groups. 

On the other hand, PCI patients presented lower freedom form revascularization and myocardial infarction. Among diabetics, global mortality was also similar in PCI and CABG groups but with greater chances of infarction, revascularization and stroke in the PCI group. 

STEMI patients receiving PCI presented a higher survival rate at 5 years, driven by its lower 30 day mortality rate (6% vs 1.5%; p=0.017). Freedom from combined events in this last group was similar. PCI was associated with repeat revascularization.

Conclusion

≤50 year patients have excellent immediate evolution with both PCI and CABG. At 5 years, PCI was associated with a significantly higher rate of infarction or repeat revascularization. 

Commentary

This analysis shows that evolution at 5 years with PCI or CABG is similar in terms or mortality. PCI is associated with higher rates of repeat revascularization and non-fatal AMI, as the large randomized studies show. In patients presenting with STEMI, PCI was superior to CABG in terms of mortality, which offers an advantage.

Carlos Fava

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary self-expanding transcatheter heart valves with intra-annular (IA)...